Patents by Inventor Trevor Baglin

Trevor Baglin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thrombin-Binding Antibody Molecules And Uses Thereof
    Publication number: 20210371543
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Application
    Filed: June 10, 2021
    Publication date: December 2, 2021
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Thrombin-binding antibody molecules and uses thereof
    Patent number: 11155637
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: October 26, 2021
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Thrombin-Binding Antibody Molecules And Uses Thereof
    Publication number: 20200002435
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Application
    Filed: June 26, 2019
    Publication date: January 2, 2020
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Thrombin-Binding Antibody Molecules And Uses Thereof
    Publication number: 20190276558
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Application
    Filed: March 25, 2019
    Publication date: September 12, 2019
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Thrombin-binding antibody molecules and uses thereof
    Patent number: 10370454
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: August 6, 2019
    Assignee: JANSSEN PHARMACEUTICALS, INC.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Modified serpins for the treatment of bleeding disorders
    Patent number: 10351619
    Abstract: This invention relates pro-coagulant serpin molecules engineered by modification of the P4, P2, P1 and/or P1? residues within the reactive center loop (RCL) to display increased specificity for anticoagulant proteases. These modified serpin molecules may be useful in therapy, for example as pro-coagulants for the treatment of bleeding.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: July 16, 2019
    Assignee: Cambridge Enterprise Limited
    Inventors: James Andrew Huntington, Stéphanie Polderdijk, Trevor Baglin
  • Thrombin-binding antibody molecules and uses thereof
    Patent number: 10287363
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: May 14, 2019
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Thrombin-Binding Antibody Molecules And Uses Thereof
    Publication number: 20180334511
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Application
    Filed: May 10, 2018
    Publication date: November 22, 2018
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Thrombin-Binding Antibody Molecules And Uses Thereof
    Publication number: 20180334512
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Application
    Filed: May 10, 2018
    Publication date: November 22, 2018
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • MODIFIED SERPINS FOR THE TREATMENT OF BLEEDING DISORDERS
    Publication number: 20180273610
    Abstract: This invention relates pro-coagulant serpin molecules engineered by modification of the P4, P2, P1 and/or P1? residues within the reactive center loop (RCL) to display increased specificity for anticoagulant proteases. These modified serpin molecules may be useful in therapy, for example as pro-coagulants for the treatment of bleeding.
    Type: Application
    Filed: May 4, 2018
    Publication date: September 27, 2018
    Inventors: James Andrew Huntington, Stéphanie Polderdijk, Trevor Baglin
  • Thrombin-binding antibody molecules and uses thereof
    Patent number: 9988463
    Abstract: This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: June 5, 2018
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Thrombin-binding antibody molecules and uses thereof
    Patent number: 9988461
    Abstract: This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: February 16, 2017
    Date of Patent: June 5, 2018
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Modified serpins for the treatment of bleeding disorders
    Patent number: 9982035
    Abstract: This invention relates pro-coagulant serpin molecules engineered by modification of the P4, P2, P1 and/or P1? residues within the reactive center loop (RCL) to display increased specificity for anticoagulant proteases. These modified serpin molecules may be useful in therapy, for example as pro-coagulants for the treatment of bleeding.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: May 29, 2018
    Assignee: Cambridge Enterprise Limited
    Inventors: James Andrew Huntington, Stéphanie Polderdijk, Trevor Baglin
  • Thrombin-Binding Antibody Molecules and Uses Thereof
    Publication number: 20170226226
    Abstract: This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Application
    Filed: February 16, 2017
    Publication date: August 10, 2017
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Thrombin-binding antibody molecules and uses thereof
    Patent number: 9605082
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: July 11, 2016
    Date of Patent: March 28, 2017
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • THROMBIN-BINDING ANTIBODY MOLECULES AND USES THEREOF
    Publication number: 20170066842
    Abstract: This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Application
    Filed: November 10, 2016
    Publication date: March 9, 2017
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Thrombin-binding antibody molecules
    Patent number: 9518128
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: December 13, 2016
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Thrombin-binding antibody molecules and uses thereof
    Patent number: 9518129
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: December 13, 2016
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Thrombin-Binding Antibody Molecules and Uses Thereof
    Publication number: 20160347862
    Abstract: This invention relates to isolated antibodies which recognise the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Application
    Filed: July 11, 2016
    Publication date: December 1, 2016
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • MODIFIED SERPINS FOR THE TREATMENT OF BLEEDING DISORDERS
    Publication number: 20160311887
    Abstract: This invention relates pro-coagulant serpin molecules engineered by modification of the P4, P2, P1 and/or P1? residues within the reactive center loop (RCL) to display increased specificity for anticoagulant proteases. These modified serpin molecules may be useful in therapy, for example as pro-coagulants for the treatment of bleeding.
    Type: Application
    Filed: December 15, 2014
    Publication date: October 27, 2016
    Applicant: CAMBRIDGE ENTERPRISE LIMITED
    Inventors: James Andrew Huntington, Stéphanie Polderdijk, Trevor Baglin